MISSISSAUGA, ON, May 12, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) (“Cipher” or “the Company”), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual Meeting of Shareholders held on May 11, 2017 in Toronto, Ontario.
A total of 20,451,102 million common shares representing 77.3% of the Company’s issued and outstanding common shares were voted in connection with the meeting. Shareholders voted in favour of all items of business put forth. The votes for the election of directors are as follows:
Motions | % of Shares Voted For | % of Shares Voted Withhold |
Elect Dr. John Mull | 87.98% | 12.02% |
Elect Harold Wolkin | 84.53% | 15.47% |
Elect Christian Godin | 86.48% | 13.52% |
Elect Mark Beaudet | 81.98% | 18.02% |
Elect Arthur Deboeck | 92.65% | 7.35% |
Elect Robert Tessarolo | 82.51% | 17.49% |
About Cipher Pharmaceuticals Inc.
Cipher (TSX:CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.
